This study is looking at how a medication called empagliflozin (10 mg) affects people with cirrhosis (severe liver scarring) and ascites (fluid buildup in the belly). Researchers want to see if empagliflozin can help your body get rid of extra salt and water. You would receive either empagliflozin or a placebo (an inactive pill) for 14 days, then have a break, and then switch to the other treatment for another 14 days. To join, you need to be at least 18 years old, have cirrhosis with ascites, be on stable diuretic (water pill) medication, and have a kidney function test (eGFR) of 30 or higher. The study is currently unclear on its recruitment status and plans to enroll 20 participants.

Study design

This is a randomized study where participants receive empagliflozin or a placebo, then switch treatments. It involves 20 participants.

What's involved

Participants will take either empagliflozin or a placebo for 14 days, have a 14-day break, and then take the other treatment for 14 days.

Compensation

Not stated in the trial record.

Follow-up

The main effects are measured after 14 days of each treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.